Unlocking CD151's Potential as A Cancer Drug Target and Biomarker
![Review Report on CD151 Target / Biomarker](https://silexon.ai/img/target-biomarker-review.jpg?a=1)
![Content of Review Report on CD151 Target / Biomarker](https://silexon.ai/img/target-biomarker-review-content.jpg?a=2)
Unlocking CD151's Potential as A Cancer Drug Target and Biomarker
CD151 Molecule as a Potential Drug Target: Unveiling its Potential Interactions and Contributions to the Battle Against Cancer
CD151 molecule, also known as CD151 transcript variant 1, is a protein that is expressed in various tissues of the human body. It plays a crucial role in the immune response, specifically in the regulation of inflammation and tissue repair. CD151 has also been implicated in cancer progression, and as such, it has potential as a drug target or biomarker. In this article, we will explore the CD151 molecule in depth, highlighting its potential as a drug target and its potential contributions to the fight against cancer.
CD151 Molecule: Structure and Function
CD151 molecule is a member of the integrin alpha-2 (ITGA2) family, which is responsible for cell adhesion, migration, and invasion. It consists of 214 amino acid residues and has a molecular weight of 24.5 kDa. CD151 molecule has four distinct isoforms, which are generated through alternative splicing of the gene. These isoforms are involved in different cellular processes, including cell adhesion, migration, and the regulation of inflammation.
CD151 molecule has been shown to play a crucial role in the regulation of inflammation and tissue repair. It is a key regulator of the T-cell receptor (TCR), which is responsible for cell recognition and activation. CD151 has been shown to regulate the activity of the TCR, allowing it to maintain a stable state in the presence of antigens.
CD151 molecule has also been shown to contribute to cancer progression. It has been shown to be involved in the regulation of cell cycle progression, as well as the angiogenesis that is the process of blood vessel formation in cancer. CD151 has been shown to promote the growth and survival of cancer cells, which suggests that it may be a potential drug target for cancer.
CD151 Molecule as a Drug Target
CD151 molecule has been identified as a potential drug target due to its involvement in the regulation of inflammation and cancer progression. One of the main goals of drug development is to identify and target molecules that are involved in cancer progression with the hope of inhibiting its progression.
One way to target CD151 molecule is through inhibition of its activity. There are several drugs that have been shown to inhibit the activity of CD151, including inhibitors of the T-cell receptor (TCR), as well as inhibitors of its downstream signaling pathways. These drugs have been shown to have therapeutic effects on various diseases, including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.
Another approach to targeting CD151 molecule is through its inhibition of the angiogenesis that is the process of blood vessel formation in cancer. CD151 has been shown to be involved in the regulation of angiogenesis, and inhibitors of its activity have been shown to have therapeutic effects on cancer growth.
CD151 Molecule as a Biomarker
CD151 molecule has also been shown to be potential biomarker for cancer. Its expression has been shown to be associated with various diseases, including breast cancer, colon cancer, and skin cancer. Additionally, its activity has been shown to be involved in the regulation of cancer progression, which suggests that it may be a useful biomarker for monitoring the effectiveness of cancer treatments.
Conclusion
CD151 molecule has a great potential as a drug target and biomarker. Its involvement in the regulation of inflammation and cancer progression makes it an attractive target for drug development. The inhibition of its activity has been shown to have therapeutic effects on various diseases, including autoimmune diseases and cancer. Further research is needed to fully understand its potential as a drug target and biomarker.
Protein Name: CD151 Molecule (Raph Blood Group)
Functions: Essential for the proper assembly of the glomerular and tubular basement membranes in kidney
The "CD151 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD151 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A